Aliskiren-attenuated myocardium apoptosis via regulation of autophagy and connexin-43 in aged spontaneously hypertensive rats

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 7, 2014, Pages 1247-1256

  Zhang, Wenbin ^a   Zhao, Gang ^b   Hu, Xiaona ^b,c   Wang, Min ^a   Li, Hua ^b   Ye, Yong ^b   Du, Qijun ^b   Yao, Jin ^b   Bao, Zhijun ^b,c   Hong, Wei ^b,c   Fu, Guosheng ^a   Ge, Junbo ^b   Qiu, Zhaohui ^b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai Key Laboratory of Traditional Chinese Clinical Medicine   (China)

Author keywords

Aged spontaneously hypertensive rats; AKT; Aliskiren; Apoptosis; Autophagy; Caspase3; Connexin 43; Survivin

Indexed keywords

ALISKIREN; AMIDE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; APOPTOSIS REGULATORY PROTEIN; CONNEXIN 43; FUMARIC ACID DERIVATIVE; MESSENGER RNA;

AGING; ANIMAL; APOPTOSIS; AUTOPHAGY; BLOOD PRESSURE; CARDIAC MUSCLE CELL; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MALE; METABOLISM; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; WESTERN BLOTTING; WISTAR KYOTO RAT;

AGING; AMIDES; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BLOOD PRESSURE; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CONNEXIN 43; FLUORESCENT ANTIBODY TECHNIQUE; FUMARATES; IMMUNOENZYME TECHNIQUES; MALE; MYOCYTES, CARDIAC; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84904987882     PISSN: 15821838     EISSN: 15824934     Source Type: Journal    
DOI: 10.1111/jcmm.12273     Document Type: Article

References (47)

1. Zhang WB, Du QJ, Li H, et al. The therapeutic effect of Rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats. J Cell Mol Med. 2012; 16: 2227-37.
2. Sun B, Huo R, Sheng Y, et al. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension. 2013; 61: 352-60.
3. Cao DJ, Wang ZV, Battiprolu PK, et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA. 2011; 108: 4123-8.
4. Rifki OF, Bodemann BO, Battiprolu PK, et al. RalGDS-dependent cardiomyocyte autophagy is required for load-induced ventricular hypertrophy. J Mol Cell Cardiol. 2013; 59: 128-38.
5. Russo SB, Baicu CF, Van Laer A, et al. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest. 2012; 122: 3919-30.
6. Mureli S, Gans CP, Bare DJ, et al. Mesenchymal stem cells improve cardiac conduction by upregulation of connexin 43 through paracrine signaling. Am J Physiol Heart Circ Physiol. 2013; 304: H600-9.
7. Vetter C, Zweifel M, Zuppinger C, et al. Connexin 43 expression in human hypertrophied heart due to pressure and volume overload. Physiol Res. 2010; 59: 35-42.
8. Huang QY, Chen YC, Liu SP. Connexin 43, angiotensin II, endothelin 1, and type III collagen alterations in heart of rats having undergone fatal electrocution. Am J Forensic Med Pathol. 2012; 33: 215-21.
9. Sheu JJ, Chang LT, Chiang CH, et al. Impact of diabetes on cardiomyocyte apoptosis and connexin43 gap junction integrity: role of pharmacological modulation. Int Heart J. 2007; 48: 233-45.
10. Goubaeva F, Mikami M, Giardina S, et al. Cardiac mitochondrial connexin 43 regulates apoptosis. Biochem Biophys Res Commun. 2007; 352: 97-103.
11. Severs NJ, Coppen SR, Dupont E, et al. Gap junction alterations in human cardiac disease. Cardiovasc Res. 2004; 62: 368-77.
12. Sheu JJ, Tsai TH, Chang LT, et al. Diabetes mellitus downregulates expression of connexin43 in rat aortic medial smooth muscle cells and can be reversed by simvastatin and losartan therapy. Chang Gung Med J. 2008; 31: 136-44.
13. Lichtenstein A, Minogue PJ, Beyer EC, et al. Autophagy: a pathway that contributes to connexin degradation. J Cell Sci. 2011; 124: 910-20.
14. Bejarano E, Girao H, Yuste A, et al. Autophagy modulates dynamics of connexins at the plasma membrane in a ubiquitin-dependent manner. Mol Biol Cell. 2012; 23: 2156-69.
15. Verdecchia P, Angeli F, Mazzotta G, et al. Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis. 2010; 4: 193-200.
16. Howard CG, Mullins JJ, Mitchell KD. Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension. Am J Med Sci. 2011; 341: 383-7.
17. van Esch JH, Moltzer E, van Veghel R, et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens. 2010; 28: 2145-55.
18. Qiu Z, Zhang W, Fan F, et al. Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCalpha/beta2 signal pathway. J Cell Mol Med. 2012; 16: 3052-61.
19. Danser AH, van Kats JP, Admiraal PJ, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension. 1994; 24: 37-48.
20. Fabris B, Candido R, Bortoletto M, et al. Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system. J Hypertens. 2011; 29: 273-81.
21. Quadrilatero J, Bloemberg D. Apoptosis repressor with caspase recruitment domain is dramatically reduced in cardiac, skeletal, and vascular smooth muscle during hypertension. Biochem Biophys Res Commun. 2010; 391: 1437-42.
22. Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol. 2007; 150: 851-61.
23. Iravanian S, Sovari AA, Lardin HA, et al. Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43. J Mol Med. 2011; 89: 677-87.
24. Sovari AA, Iravanian S, Dolmatova E, et al. Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death. J Am Coll Cardiol. 2011; 58: 2332-9.
25. Hussain W, Patel PM, Chowdhury RA, et al. The Renin-Angiotensin system mediates the effects of stretch on conduction velocity, connexin43 expression, and redistribution in intact ventricle. J Cardiovasc Electrophysiol. 2010; 21: 1276-83.
26. Fialova M, Dlugosova K, Okruhlicova L, et al. Adaptation of the heart to hypertension is associated with maladaptive gap junction connexin-43 remodeling. Physiol Res. 2008; 57: 7-11.
27. Zhao LL, Chen HJ, Chen JZ, et al. Losartan reduced connexin43 expression in left ventricular myocardium of spontaneously hypertensive rats. J Zhejiang Univ Sci B. 2008; 9: 448-54.
28. Bacharova L, Plandorova J, Klimas J, et al. Discrepancy between increased left ventricular mass and "normal" QRS voltage is associated with decreased connexin 43 expression in early stage of left ventricular hypertrophy in spontaneously hypertensive rats. J Electrocardiol. 2008; 41: 730-4.
29. Paull JR, Widdop RE. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. J Hypertens. 2001; 19: 1393-402.
30. Gouldsborough I, Lindop GB, Ashton N. Renal renin-angiotensin system activity in naturally reared and cross-fostered spontaneously hypertensive rats. Am J Hypertens. 2003; 16: 864-9.
31. Takemori K, Ishida H, Ito H. Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive rats. Life Sci. 2005; 77: 2233-45.
32. Miro-Casas E, Ruiz-Meana M, Agullo E, et al. Connexin43 in cardiomyocyte mitochondria contributes to mitochondrial potassium uptake. Cardiovasc Res. 2009; 83: 747-56.
33. Radosinska J, Bacova B, Bernatova I, et al. Myocardial NOS activity and connexin-43 expression in untreated and omega-3 fatty acids-treated spontaneously hypertensive and hereditary hypertriglyceridemic rats. Mol Cell Biochem. 2011; 347: 163-73.
34. Yoshioka J, Prince RN, Huang H, et al. Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF. Proc Natl Acad Sci USA. 2005; 102: 10622-7.
35. Kostin S, Dammer S, Hein S, et al. Connexin 43 expression and distribution in compensated and decompensated cardiac hypertrophy in patients with aortic stenosis. Cardiovasc Res. 2004; 62: 426-36.
36. Li AF, Roy S. High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. Invest Ophthalmol Vis Sci. 2009; 50: 1400-7.
37. Gilleron J, Carette D, Durand P, et al. Connexin 43 a potential regulator of cell proliferation and apoptosis within the seminiferous epithelium. Int J Biochem Cell Biol. 2009; 41: 1381-90.
38. Alonso F, Krattinger N, Mazzolai L, et al. An angiotensin II- and NF-kappaB-dependent mechanism increases connexin 43 in murine arteries targeted by renin-dependent hypertension. Cardiovasc Res. 2010; 87: 166-76.
39. Zhao G, Wang S, Wang Z, et al. CXCR6 deficiency ameliorated myocardial ischemia/reperfusion injury by inhibiting infiltration of monocytes and IFN-gamma-dependent autophagy. Int J Cardiol. 2013; 168: 853-62.
40. Wang Y, Li YB, Yin JJ, et al. Autophagy regulates inflammation following oxidative injury in diabetes. Autophagy. 2013; 9: 272-7.
41. Pan W, Zhong Y, Cheng C, et al. MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS ONE. 2013; 8: e53950.
42. Dai DF, Rabinovitch P. Mitochondrial oxidative stress mediates induction of autophagy and hypertrophy in angiotensin-II treated mouse hearts. Autophagy. 2011; 7: 917-8.
43. Schmerbach K, Pfab T, Zhao Y, et al. Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. PLoS ONE. 2010; 5: e15052.
44. Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011; 32: 1227-34.
45. Dong YF, Liu L, Kataoka K, et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia. 2010; 53: 180-91.
46. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007; 50: 2398-404.
47. Wood JM, Schnell CR, Cumin F, et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005; 23: 417-26.